Core Viewpoint - AngioDynamics, Inc. is expected to report a quarterly loss of 10 cents per share for Q2 FY26, which is a decline from a loss of 4 cents per share in the same quarter last year, while revenue is projected to increase to $76.43 million from $72.84 million year-over-year [1] Group 1: Earnings Expectations - The company will release its Q2 earnings results on January 6, 2026, before the market opens [1] - Analysts anticipate a quarterly loss of 10 cents per share, compared to a loss of 4 cents per share in the previous year [1] - The consensus estimate for quarterly revenue is $76.43 million, an increase from $72.84 million a year earlier [1] Group 2: Stock Performance - AngioDynamics shares fell by 1.8% to close at $12.87 on the previous Friday [2] Group 3: Analyst Ratings - Canaccord Genuity analyst William Plovanic maintained a Buy rating and raised the price target from $17 to $18 on October 3, 2025, with an accuracy rate of 62% [3] - HC Wainwright & Co. analyst Yi Chen also maintained a Buy rating with a price target of $16 on July 16, 2025, achieving an accuracy rate of 66% [3]

Core Insights - AngioDynamics (ANGO) is showing improved execution in the market despite not receiving full recognition [1] - The Medical Tech segment is driving solid growth for the company, indicating a focus on faster-growing areas [1] Company Performance - AngioDynamics continues to make progress, albeit slowly, which is still considered positive [1] - The company is experiencing growth in its Medical Tech segment, which is a key driver of its performance [1]

Group 1 - The core viewpoint is that AngioDynamics (ANGO) is making slow but steady progress, with improved execution in the market despite not receiving full recognition [1] - The Medical Tech segment is identified as the key driver of solid growth for the company, indicating a focus on faster-growing areas within the industry [1]

Core Insights - AngioDynamics is undergoing a significant transformation to shift from a traditional device manufacturer to a focused MedTech company targeting large addressable markets with high gross margins [2][3] Company Overview - AngioDynamics operates on a unique fiscal year that begins on June 1, with the second quarter of FY 2026 nearing completion in three weeks [2] - The company has spent the last five years restructuring its portfolio to enhance competitiveness and focus on areas where it can achieve success [2][3]

Summary of AngioDynamics Conference Call Company Overview - **Company**: AngioDynamics (NasdaqGS: ANGO) - **Fiscal Year**: The company operates on a unique fiscal year starting June 1, currently nearing the end of Q2 for FY 2026 - **Transformation**: AngioDynamics is undergoing a transformation from a diversified medical device company to a focused MedTech company targeting large addressable markets with high gross margins [4][6][8] Key Points on Transformation and Financial Performance - **Revenue Shift**: The MedTech business has grown from less than 17% of total revenue to approximately 45%, with expectations to surpass 50% soon [8][10] - **EBITDA Positive**: The company achieved adjusted EBITDA positivity last fiscal year and expects to maintain this going forward [8][10] - **Cash Flow**: AngioDynamics anticipates being cash flow positive for the fiscal year ending May 31 [9][10] - **Growth Rate**: The MedTech segment has experienced a compound annual growth rate (CAGR) of about 25% over the last five years [12] MedTech Business Insights - **Market Focus**: The MedTech portfolio includes two cardiovascular areas and one interventional oncology area, with significant growth potential in each [14][15] - **Key Products**: - **NanoKnife**: Recently approved for treating intermediate-risk prostate cancer, with a market potential of over $2 billion globally [14][15][75] - **Arion System**: Launched in 2020, it has grown to over $60 million in revenue, focusing on peripheral arterial disease (PAD) [6][43] - **AlphaVac System**: Competing in the venous thromboembolism (VTE) market, showing a 40% growth in Q1 [20][21] Market Dynamics and Growth Drivers - **Interventional Oncology**: The NanoKnife product addresses a significant market need, with a focus on preserving quality of life for patients [78][80] - **Cardiovascular Market**: The company is expanding into coronary interventions, which represent a larger market opportunity [15][46] - **VTE Market**: The mechanical thrombectomy market is expected to grow, with AngioDynamics taking market share from competitors [20][23] Challenges and Opportunities - **Macro Environment**: The healthcare sector faces pressures from Medicare and Medicaid changes, but AngioDynamics believes its product mix positions it well to navigate these challenges [17][18] - **Clinical Evidence**: Ongoing studies and clinical data generation are crucial for market adoption and confidence in mechanical thrombectomy and other products [25][41][58] Financial Outlook - **Sales Growth Guidance**: For FY 2026, AngioDynamics projects overall sales growth of 5-7%, with double-digit growth expected in the MedTech segment [94][98] - **Capital Allocation**: The company plans to focus on innovation within its existing MedTech business rather than pursuing external M&A in the near term [91][93] Conclusion - AngioDynamics is strategically positioned for growth in the MedTech sector, with a strong focus on innovation, clinical evidence, and market expansion. The company is optimistic about its financial trajectory and the potential for its products to capture significant market share in the coming years [84][88][90]

Core Insights - AngioDynamics, Inc. will participate in the UBS Global Healthcare Conference on November 10, 2025, with CEO Jim Clemmer and CFO Stephen Trowbridge presenting [1] - The company's NanoKnife System has been recognized as one of TIME's 2025 Best Inventions, highlighting its innovative impact in medical technology [6] - AngioDynamics reported a net sales figure of $75.7 million for the first quarter of fiscal year 2026, reflecting a year-over-year growth of 26.1% in the medical technology sector [7] Company Overview - AngioDynamics is a medical technology company focused on restoring healthy blood flow, expanding cancer treatment options, and improving patient quality of life [3][6] - The company’s innovative technologies are utilized by physicians in rapidly growing healthcare markets to address unmet patient needs [3] Financial Performance - For the first quarter of fiscal year 2026, which ended on August 31, 2025, AngioDynamics achieved net sales of $75.7 million, indicating strong growth in the medical technology sector [7]

Core Insights - AngioDynamics, Inc. will participate in the UBS Global Healthcare Conference on November 10, 2025, with CEO Jim Clemmer and CFO Stephen Trowbridge presenting [1] - The company's NanoKnife System has been recognized as one of TIME's 2025 Best Inventions, highlighting its innovative impact on healthcare [6] Financial Performance - For the first quarter of fiscal year 2026, AngioDynamics reported net sales of $75.7 million, reflecting a year-over-year growth of 26.1% in the medical technology sector [7]

Core Insights - AngioDynamics, Inc. (NASDAQ:ANGO) is highlighted as a small-cap stock with significant upside potential, supported by a Buy rating from H.C. Wainwright and a price target of $16 following strong fiscal Q1 2026 results [1][2]. Financial Performance - The company reported net sales of $75.7 million for Q1 2026, reflecting a year-over-year increase of 12.2%, primarily driven by a 26.1% rise in Med Tech revenue [2]. - Key products, AlphaVac and AngioVac, experienced substantial sales growth, with increases of over 50% and 37% respectively, contributing to a 91% stock return over the past year [2]. - Despite a net loss of $10.9 million, AngioDynamics achieved a positive adjusted EBITDA of $2.2 million [3]. - U.S. and international sales grew by 11.7% and 15.6%, respectively [3]. - The company raised its full-year guidance, projecting net sales between $308 million and $313 million, and adjusted EBITDA between $6.0 million and $10.0 million, while maintaining its gross margin outlook [3]. Company Overview - AngioDynamics is a global medical technology company that develops, produces, and markets devices for treating peripheral vascular disease, cancer, and surgical conditions, supporting both diagnostic and therapeutic procedures in U.S. and international healthcare markets [4].

Core Insights - AngioDynamics, Inc. reported a narrower-than-expected loss per share of $0.10 for Q1 fiscal 2026, surpassing the Zacks Consensus Estimate of a $0.14 loss, and showing improvement from the previous year's adjusted loss of $0.11 per share [1][6] - The company's revenue for the quarter was $75.71 million, slightly below the estimated $75.94 million, but still represents a 12.2% increase from the previous year, driven by a 26.1% increase in its Med Tech segment [2][6] - Following the earnings report, AngioDynamics raised its fiscal year 2026 sales outlook to a range of $308 million to $313 million, indicating confidence in continued growth [2][6] Financial Performance - The pro-forma adjusted figures showed a GAAP loss per share of $0.26, an improvement from the previous year's loss of $0.32, despite a negative price-to-earnings (P/E) ratio of -14.44 [3] - The company's gross profit margin increased to 55.3%, which is 90 basis points higher than the previous year, although GAAP-calculated earnings were lower than the adjusted profit of $0.10 per share [4] - AngioDynamics maintains a strong liquidity position with a current ratio of 2.29, indicating it has more than twice the amount of current assets compared to its current liabilities [3] Market Reaction - Following the earnings report, AngioDynamics' stock surged by 10.5% by 11:25 a.m. ET, reflecting investor confidence in the company's performance and future prospects [4] - Despite financial ratio challenges, such as a price-to-sales ratio of 1.53 and an enterprise value to operating cash flow ratio of -49.91, the company continues to focus on its core operations [5]

Core Insights - AngioDynamics, Inc. reported stronger-than-expected first-quarter results and raised its fiscal 2026 guidance, indicating growth across its Med-Tech businesses [1][3] Financial Performance - First-quarter revenue increased by 12.1% to $75.7 million, exceeding consensus estimates, driven by a 26.2% rise in Med-Tech sales [2] - Gross margin improved to 55.3%, surpassing the expected 52.5% [2] - Adjusted EPS showed a loss of 10 cents, slightly below forecasts, while adjusted EBITDA reached $2.2 million, exceeding estimates [2] Fiscal Guidance - Fiscal year 2026 revenue guidance was raised to between $308 million and $313 million, reflecting a projected Med-Tech growth of 14% to 16% [3] - Adjusted EBITDA is now expected to range from $6 million to $10 million, with positive cash flow anticipated for the year [3] - Gross margin guidance remains steady at 53.5%-55.5%, despite challenges from manufacturing transitions and raw material costs [3] Product Performance - Mechanical Thrombectomy revenue grew by 41.2% year-over-year to $11.3 million, with strong performance from AngioVac and AlphaVac [4] - Auryon generated $16.5 million in revenue, up 20.1% year-over-year, benefiting from expansion in outpatient labs and hospitals [5] - NanoKnife revenue reached $6.4 million, a 26.7% year-over-year increase, with disposables sales exceeding forecasts [5] Financial Position - AngioDynamics ended the quarter with $38.8 million in cash, no debt, and full access to a $25 million revolving credit facility [6] - Management anticipates approximately $3 million in cash burn in the second quarter before achieving positive cash flow in the second half [6] - Canaccord projects revenue of $310.9 million for fiscal year 2026 and $325.1 million for fiscal year 2027, slightly adjusted from previous estimates [6]